MX2023007870A - Compuestos y metodos para modular el fxr. - Google Patents

Compuestos y metodos para modular el fxr.

Info

Publication number
MX2023007870A
MX2023007870A MX2023007870A MX2023007870A MX2023007870A MX 2023007870 A MX2023007870 A MX 2023007870A MX 2023007870 A MX2023007870 A MX 2023007870A MX 2023007870 A MX2023007870 A MX 2023007870A MX 2023007870 A MX2023007870 A MX 2023007870A
Authority
MX
Mexico
Prior art keywords
compounds
methods
modulating fxr
fxr
modulating
Prior art date
Application number
MX2023007870A
Other languages
English (en)
Inventor
Kevin Klucher
Yingzi Xu
F Anthony Romero
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of MX2023007870A publication Critical patent/MX2023007870A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

En la presente descripción se describen compuestos que pueden usarse como agonistas del receptor X farnesoide (FXR), composiciones que contienen estos compuestos y métodos para usarlos.
MX2023007870A 2020-12-30 2021-12-29 Compuestos y metodos para modular el fxr. MX2023007870A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063132363P 2020-12-30 2020-12-30
PCT/US2021/073153 WO2022147448A1 (en) 2020-12-30 2021-12-29 Compounds and methods for modulating fxr

Publications (1)

Publication Number Publication Date
MX2023007870A true MX2023007870A (es) 2023-11-09

Family

ID=82258672

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007870A MX2023007870A (es) 2020-12-30 2021-12-29 Compuestos y metodos para modular el fxr.

Country Status (13)

Country Link
US (1) US20240116912A1 (es)
EP (1) EP4271377A1 (es)
JP (1) JP2024501700A (es)
KR (1) KR20230142478A (es)
CN (1) CN116887827A (es)
AU (1) AU2021413366A1 (es)
CA (1) CA3207069A1 (es)
CL (1) CL2023001913A1 (es)
CO (1) CO2023009817A2 (es)
IL (1) IL304121A (es)
MX (1) MX2023007870A (es)
PE (1) PE20240118A1 (es)
WO (1) WO2022147448A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7450951B2 (ja) * 2022-02-17 2024-03-18 カスケード ファーマシューティカルズ、インコーポレーテッド 新型ｆｘｒ小分子作動剤の製造およびその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360464A (en) * 1969-11-28 1982-11-23 Teikoku Hormone Mfg. Co. Ltd. Process for production of 1-aryloxy-aminopropane derivatives
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
US10080742B2 (en) * 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
JP7093341B2 (ja) * 2016-08-23 2022-06-29 アルデリックス， インコーポレイテッド 代謝異常状態及び代謝障害を治療するためのホルモン受容体調節薬
WO2020211872A1 (zh) * 2019-04-19 2020-10-22 中国科学院上海药物研究所 Fxr小分子激动剂及其制备方法和用途

Also Published As

Publication number Publication date
JP2024501700A (ja) 2024-01-15
WO2022147448A1 (en) 2022-07-07
CL2023001913A1 (es) 2024-02-09
CA3207069A1 (en) 2022-07-07
CN116887827A (zh) 2023-10-13
CO2023009817A2 (es) 2023-09-08
EP4271377A1 (en) 2023-11-08
KR20230142478A (ko) 2023-10-11
AU2021413366A1 (en) 2023-08-17
US20240116912A1 (en) 2024-04-11
PE20240118A1 (es) 2024-01-22
IL304121A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
EA202190726A1 (ru) Индольные ингибиторы арил-гидрокарбонового рецептора (ahr) и их применение
MX2022014548A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
PH12018501656A1 (en) Methods for using fxr agonists
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
MX2018012087A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2021012216A (es) Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
MX2022014007A (es) Compuestos como inhibidores de bcl-2.
CL2023001913A1 (es) Compuestos y métodos para modular el fxr.
NZ729618A (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
PH12021550049A1 (en) Selective estrogen receptor degraders.
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
PH12019502326A1 (en) An isoxazole derivatives as nuclear receptor agonists and used thereof
WO2018237379A3 (en) COMPOUNDS MODULATING THE PATH OF SPHINGOSINE FOR THE TREATMENT OF CANCERS
PH12017502123A1 (en) Substituted benzamides and methods of use thereof
UA105000C2 (uk) ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ СТЕАРОЇЛ-СоА-ДЕСАТУРАЗИ
MX2018016384A (es) Inhibidores de hidrato de gas.
MX2023011933A (es) Moduladores del linfoma de linaje b de casitas de ligasa e3 b (cbl-b) y usos de estos.
WO2021158635A8 (en) Anti-viral compositions and methods of use
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
WO2022221528A3 (en) Kras g12c inhibitors
WO2022245900A3 (en) Compositions for treating inflammatory, neurologic and/or vascular conditions and methods of use thereof
MX2023003973A (es) Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos.
MX2023009724A (es) Sustitucion de amoniaco en productos para alterar el cabello.
MX2022014126A (es) Moduladores de enpp1 y usos de los mismos.